TARA trial: Ph3 H2H trial of Girocitinib (JAK1/TYK2i) vs Tofa in RA refractory to bDMARDs Giro achieved higher ACR50 response vs Tofa at wk24 (73 vs 49.5%) Also met secondary endpts Safety data: Infections more common. No VT/malignancy/MACE in Giro arm. @RheumNow #ACR26 LB21 https://t.co/HNVt7WdLc6

Efgartigimod comes in with the first successful ph3 for IMNM (ALKIVIA trial) Nipocalimab ph2 missed primary but big numerical diff FcRN prob an obvious target for IMNM In a debilitating disease with minimal other options, it's a very good time ABSTLB24 ABST0905 #ACR26 @RheumNow https://t.co/c6RapsKKla

REDUCE-2: Ph 3 RCT of oral Pozdeutinurad (highly selective URAT-1i) for #gout Sign reduxn of SU <6 mg/dL at mo 6, 69% for 75mg, 58% for 50mg. Rapid onset of clinically meaningful SU reduxns & sustained thru 12mos Well-tolerated, low renal AEs @RheumNow #ACR26 LB20 https://t.co/nqzDHM6rJP

#unmet need for #urate #lowering in #gout w #URAT1i #pozdeutinurad Tophi 1/4 >8 baseline uric acid (American units) Sustained uric acid over time Benefit from 6mo onward Rare EAs /SAEs DBRCT 2 doses, 75&150mg works Some failed other prior Rx #ACR26 #ACRbest @RheumNow #LB20 https://t.co/83aCtazXwt

BREAKING: Reports that Novartis still working on IEC-HS investigation after rap-cel CAR-T deaths. Georg Schett calls lack of details "very sad" & has submitted commentary to @NEJM (with Carl June, CAR-T inventor) to discuss it https://t.co/Tn2svGi0BP #ACR26 @RheumNow https://t.co/5ZJ8pGCQg7

We do GCA studies with new-onset & relapsing data mixed in, for practical purposes. Yet this is a sometimes phasic disease in SELECT-GCA (upadacitinib), those randomized to stop upa at 52w relapsed far less if new-onset (vs prev relapsing) *different* ABST2122 #ACR26 @RheumNow https://t.co/NMOIBONjar

TRBV9 is implicated in HLA-B27 disease T cell expansion (as seen @Nature https://t.co/2IhGwoH51w) Can you use it as a target? Pre-clinical TRBV9xCD3 bispecific T cell engager Might cleanly knock these out & preserve broad T cell immunity One to watch ABSTLB01 #ACR26 @RheumNow https://t.co/6j80aAw5Qq

A potential new ULT for gout: URAT1 inhibitor Abstract LB20 found that Pozdeutinurad (HD & LD) vs PBO: - more achieved SU < 6 mg/dl at month 6: 69.2% & 56.6% vs 8.1% - SU < 6 rapid and sustained until month 12 - renal AE similar across all groups @RheumNow #ACR26 https://t.co/5LXOTwwUaa

How should race and ethnicity be used in rheumatology guidelines? On the final day of #ACR26, I’ll discuss the evidence alongside Sam Lim and Candace Feldman. Join us at 10-11am in W415A! @RheumNow https://t.co/VCHa4x5MlN https://t.co/KQKPmrxupf

Ph 2A study on OSCA for knee OA showed single inj was well tolerated w/ sustained relief at 6 mos Decr sIL-1B, sCOMp, uCTX-II at mo 6. @RheumNow #ACR26 LB19 https://t.co/22jWTu8DCu

We've seen CTLA-4 agonists - abatacept 20y in practice We've seen PD-1 agonists - rosnilimab's phase 2b What about other immune checkpoint agonists, though? LAG-3 we know from ICI therapy (relatlimab) Prepare to see LAG-3 agonist drug development soon ABSTLB09 #ACR26 @RheumNow https://t.co/2l5skS1ZMY

I've had plenty of time to contemplate BE-BOLD (#EULAR2026, yesterday's #ACR26 plenary) It's still amazes me one good PsA bDMARD clearly outguns the equal next best PsA bDMARD Joints, over time. Not some compound measure early on. Can't wait for paper ABST2804 #ACR26 @RheumNow https://t.co/Wh6tzea7wd